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We read with interest the letter by Halvorsen et al.1 These authors demonstrated in Table 11 that the 
number needed to invite to prevent one melanoma death is inversely proportional to the mortality 
rate in the cohort. Whether or not a screening trial is feasible depends on this and many other 
factors, including the primary outcome, incidence, the screening test’s accuracy, and contamination 
of the control group (in the case of a melanoma screening by opportunistic skin checks).  
The US Preventive Services Task Force suggested to “…focus on evaluating the effectiveness of 
targeted screening in those considered to be at higher risk for skin cancer”, but Halvorsen et al.1 
considered it “unrealistic” to identify high-risk individuals. Improvements in risk prediction,2 online 
risk calculators,3 risk factor information available in ongoing cohort studies or sampling from 
national health insurance records may enable a risk-stratified approach. This would reduce the 
required trial sample size, and overdiagnosis compared with age-based screening.4 New 
technologies such as total-body photography plus dermoscopy, and artificial intelligence,5 rather 
than making a trial “obsolete”, could be incorporated into the trial design and lead to improvements 
in sensitivity, specificity, and benign to malignant excision ratio, thus making screening more cost-
effective and also assisting to overcome the risk of contamination of the control group. We agree 
that detection of keratinocyte cancers as part of a screening program “adds to the costs and high 
workload” but excluding the impact they have on quality of life would underestimate the benefits 
gained from their improved diagnosis and early excision.6,7  
In summary, we believe a trial may be feasible with a different design or conducted in other regions 
of the world where melanoma is more common. By providing stringent quality control, follow-up 
and reminder procedures, systematic screening could overcome many of the downfalls of 
opportunistic screening that exacerbate socio-demographic inequities in melanoma outcomes, and 
lead to many, potentially avoidable, excisions in worried-well population subgroups. Given that most 
melanomas are visible on the skin, and morbidity and mortality directly correlate with the extent of 
local invasion of the tumour at diagnosis, early detection is feasible and crucial. From an economic 
perspective, recent developments in immunotherapy treatment for late-stage disease are placing an 
increasingly unsustainable burden on the health care system. The feasibility of a randomised trial to 
assess the benefits, costs, and harms of a targeted melanoma screening program remains worthy of 
further consideration.  
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